Advanced search
Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 26, 2019 - Issue 2
Submit an article Journal homepage
229
Views
7
CrossRef citations to date
0
Altmetric
Letter to the Editor

Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

Lisa Xingguang LeeThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA
,
Ping ZhouThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA
,
Cindy VargaThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA
,
Teresa FogarenThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA
,
Katelynn HoTufts University School of Medicine, Boston, MA, USA
,
Xun MaThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA
,
Melissa WarnerThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA
,
Denis ToskicThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USAORCID Iconhttp://orcid.org/0000-0002-3340-762X
ORCID Icon,
Adin KugelmassThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA
&
Raymond L. ComenzoThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA;Department of Pathology and Clinical Laboratory Medicine, Tufts Medical Center, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6255-5824
ORCID Icon show all
Pages 101-102 | Received 08 Aug 2018, Accepted 25 Mar 2019, Published online: 23 May 2019
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days
"Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms." Amyloid, 26(2), pp. 101–102

Disclosure statement

No potential conflict of interest was reported by the authors.

Acknowledgements

The authors thank the Division of Hematology-Oncology and Departments of Medicine and Pathology and Laboratory Medicine at Tufts for their continued support, and also acknowledge the support by the Amyloidosis and Myeloma Research Fund at Tufts, the Cam Neely and John Davis Myeloma Research Fund, the John C Davis Program for Myeloma and Amyloid at Tufts, the Sidewater Family Fund, the Lavonne Horowitz Trust, the Werner and Elaine Dannheiser Fund for Research on the Biology of Aging of the Lymphoma Foundation, David and Barbara Levine (in memoriam), and the Demarest Lloyd Jr Foundation.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 903.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.